Texas Biomedical Research Institute

Texas Biomedical Research Institute, doing business as Southwest Foundation for Biomedical Research, operates as a non-profit prime contractor and recipient for the federal government, delivering preclinical infectious disease research using non-human primate models and related laboratory services to HHS, DoD, and other civilian federal agencies. The institute hosts the Southwest National Primate Research Center (SNPRC), one of seven NIH-funded national primate research centers, maintaining a colony of approximately 3,000 non-human primates including rhesus macaques, baboons, marmosets, and pigtail macaques for Good Laboratory Practice natural history studies, vaccine development, and pathogenesis research across HIV/SIV, tuberculosis, filovirus, and emerging infectious disease programs.

Texas Biomedical Research Institute operates predominantly as a prime contractor (71% of awards) rather than as a subcontractor, and competes in full-and-open federal acquisitions without SBA set-aside designations. The institute's customer base is heavily concentrated in the federal research and preparedness establishment. The National Institute of Allergy and Infectious Diseases (NIAID) accounts for 114 awards worth $282.9 million in combined potential value across 66% of the source award population. The Office of the Assistant Secretary for Preparedness and Response (ASPR) anchors the second-largest customer concentration at $112.3 million across five awards, followed by the Department of the Army at $16.8 million across four awards. NIAID and HHS collectively dominate both award count and dollar concentration, reflecting the institute's core mission in infectious disease research and pandemic preparedness.

The institute's contract portfolio centers on two single-award indefinite delivery contracts with substantial dollar exposure. The Pre-Clinical Models of Infectious Diseases IDC, awarded by NIAID on July 15, 2024, carries a $146.3 million ceiling through July 14, 2031, supporting development and refinement of animal models for evaluating countermeasures against pandemic pathogens and antimicrobial-resistant organisms. The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases IDC, awarded September 30, 2025, holds a $136.6 million ceiling extending to September 29, 2035. The ASPR IDIQ for biological animal model and medical countermeasure development services carries a $100 million ceiling through September 29, 2027, with two substantive delivery orders issued to date: a $12.1 million filovirus natural history studies order (BIO-AMT-2303, extending through September 28, 2028) and a $145 thousand contract management support order (BIO-AMT-2301, through July 19, 2027).

Texas Biomedical Research Institute operates as a prime recipient on a large and active federal research grant portfolio dominated by NIAID-funded infectious disease investigations. Recent grant awards include $962 thousand for chikungunya virus neuropathogenesis modeling (CFDA 93.855, R01, awarded September 1, 2026, through August 31, 2031); $905 thousand for epigenetic mechanisms driving intestinal epithelial dysfunction in HIV/SIV infection under the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847, awarded September 1, 2026, through July 31, 2030); $824 thousand for comparative investigation of bacterial antigen presentation in tuberculosis and tularemia under NIAID (CFDA 93.855, awarded August 1, 2026, through July 31, 2031); and $297 thousand for targeting super-enhancers to regulate HIV transcription and latency (CFDA 93.855, awarded September 1, 2026, through August 31, 2028). Additional notable grants include $927 thousand for IL-21-IGFC therapy to enhance pulmonary immune reconstitution in MTB/SIV co-infection (awarded May 11, 2026, through April 30, 2031), and three NIDA-funded awards totaling over $2.6 million for CNS HIV/SIV reservoir reduction using focused ultrasound, CRISPR gene editing, and cannabinoid therapeutics (awards September 1, 2025, through May 31, 2030). The Economic Development Administration awarded $13.6 million on May 20, 2024, for construction of a pandemic preparedness facility designed for resiliency to natural disasters and grid failure.

The institute's contract work reflects its core capability in non-human primate infectious disease modeling and vaccine development. Recent prime contracts include a $12.1 million cost-plus-fixed-fee delivery order for Good Laboratory Practice natural history studies of filovirus infection in non-human primate models (awarded September 29, 2023, to ASPR, completion September 28, 2028); a $237 thousand firm-fixed-price purchase order from CDC Pittsburgh for baboon studies (awarded September 15, 2022, completed September 14, 2023); a $193 thousand FDA purchase order for provision of baboons for OMV-pertussis vaccine studies (awarded September 27, 2023, completed September 29, 2024); and a $99 thousand NCATS order for in vitro and in vivo studies of the compound ROC-325 against live SARS-CoV-2 models (awarded August 30, 2022, completed August 31, 2024).

The institute participates as a subcontractor on federal contracts and grants across infectious disease, vaccine development, and epidemiological research programs. Recent contract sub-awards include correlate-of-protection studies for Sudan virus vaccine development under Advanced Technology International (November 15, 2024); influenza candidate vaccine virus development under Cherokee Nation Operational Solutions (September 23 and September 29, 2023); and BSL-4 challenge material production under Gap Solutions, Inc. (March 13, 2024). Grant sub-award roles span host protein characterization for filovirus infection (University of Pennsylvania, multiple years 2023–2026), monkeypox virus generation and characterization (Icahn School of Medicine at Mount Sinai, August 18, 2026), and tissue banking and genetic data management for the Strong Heart Study under multiple lead grantees (Columbia University, University of Texas Health Science Center at San Antonio, and others, spanning 2024–2026).

Award trajectory shows growth from 19 awards in 2022 to 45 awards in 2024, with 34 awards in 2025 and 27 awards in 2026, reflecting sustained federal demand for the institute's primate research capabilities and pandemic preparedness infrastructure. Seventeen awards with combined potential value of $12.3 million reach ultimate completion within the next twenty-four months, presenting recompete opportunity.

SCI-reportable service contract data, covering only contracts exceeding the $150 thousand threshold, shows $1.3 million in invoiced revenue across FY2024–FY2025 on prime records, with 0.7 FTEs delivered in FY2025. The institute generated $32 thousand at $58.62 per hour in FY2024 across 0.3 FTEs on a single prime delivery order. These figures represent a narrow slice of the institute's federal services activity and a smaller subset of total enterprise revenue; the grant and contract portfolios above capture the breadth of the institute's federal mission.